Clinical Trial Update: A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing two dosing regimens of Fabrazyme (agalsidase beta) in treatment-naïve, male pediatric Fabry disease patients has completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-06-29